What troubles me about this selloff is the volume, you have to go back to March to see this kind of volume. Having said that, we have big institutional ownership and somebody (s) may have wanted out.
Anyone know what might be driving today's sell off ?
This is what keeps me here:
As the "only selective PI3K-gamma inhibitor" in clinical development, IPI-549 has the potential to offer a unique approach within the emerging field of immuno-therapy. A Phase 1 study of IPI-549 in patients with advanced solid tumors is ongoing
why so quiet on this board, this stock is about to rocket, Q2 earnings and the conference presentations this week, momentum up. Then later this year and 2018 if their drug gets positive results and FDA approval, buyout by a big pharma, look out.
Yahoo Finance Insights
INFI is up 9.32% to 1.86
I like the movement today.
I think INFI is due for a pullback. What are your thoughts? have you guys heard of awe.some.stock_s. i started receiving their allerts and so far i am happy.
it was the Russell, INFI was deleted, so institutions with certain policies had to dump stock....it will be back.
Infinity Pharmaceuticals Inc. NASDAQ $INFI Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
Great Volume today !
Yahoo Finance Insights
INFI is down -10.20% to 1.80
traders ringing the register? buy the dip?
DTRX $1.3 this friday
(AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Steer clear of dollar stocks when economy has been growing
Let's see if Verastem positively affects Infinity today !
INFI, looks to be overvalued at this price Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awesome.stock.s.
Does anybody remember why they got into this stock to begin with? Expectation?
Who says INFI isn't poised for potentially massive upward movement? check out awesom-eSTOCKS, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.